MAP2K7 and cancer: MEK inhibitors, including trametinib (the 2D structure is shown in Figure 1B) [16,17,18], selumetinib [19] and binimetinib, have been used as a rational multi-therapy strategy to treat RAS-RAF-MEK-ERK pathway-related cancers.